UA127372C2 - Моноспецифічне pd-1-сполучне моноклональне антитіло - Google Patents

Info

Publication number

UA127372C2

UA127372C2 UAA201801414A UAA201801414A UA127372C2 UA 127372 C2 UA127372 C2 UA 127372C2 UA A201801414 A UAA201801414 A UA A201801414A UA A201801414 A UAA201801414 A UA A201801414A UA 127372 C2 UA127372 C2 UA 127372C2

Authority

UA

Ukraine

Prior art keywords

mat

domain

cancer

binding

domains

Prior art date

2015-07-30

Links

• Espacenet
• Global Dossier
• Discuss

• 230000027455 binding Effects 0.000 claims abstract description 534
• 101710058551 RO-1 Proteins 0.000 claims description 227
• 241000282414 Homo sapiens Species 0.000 claims description 211
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 188
• 210000004027 cell Anatomy 0.000 claims description 101
• 238000006467 substitution reaction Methods 0.000 claims description 90
• 206010028980 Neoplasm Diseases 0.000 claims description 76
• 201000011510 cancer Diseases 0.000 claims description 50
• 230000004048 modification Effects 0.000 claims description 49
• 238000012986 modification Methods 0.000 claims description 49
• 150000001413 amino acids Chemical class 0.000 claims description 48
• 230000035772 mutation Effects 0.000 claims description 22
• 230000002829 reductive effect Effects 0.000 claims description 22
• 239000008194 pharmaceutical composition Substances 0.000 claims description 21
• 238000011282 treatment Methods 0.000 claims description 19
• 210000002966 serum Anatomy 0.000 claims description 15
• 238000005734 heterodimerization reaction Methods 0.000 claims description 14
• 230000000903 blocking effect Effects 0.000 claims description 13
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 12
• 206010038389 Renal cancer Diseases 0.000 claims description 12
• 241000283707 Capra Species 0.000 claims description 10
• 206010009944 Colon cancer Diseases 0.000 claims description 10
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 10
• 206010039491 Sarcoma Diseases 0.000 claims description 10
• 201000010982 kidney cancer Diseases 0.000 claims description 10
• 230000001394 metastastic effect Effects 0.000 claims description 10
• 206010061289 metastatic neoplasm Diseases 0.000 claims description 10
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
• 230000008859 change Effects 0.000 claims description 8
• 206010017758 gastric cancer Diseases 0.000 claims description 8
• 201000011549 stomach cancer Diseases 0.000 claims description 8
• 102000039446 nucleic acids Human genes 0.000 claims description 7
• 108020004707 nucleic acids Proteins 0.000 claims description 7
• 150000007523 nucleic acids Chemical class 0.000 claims description 7
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
• 206010033128 Ovarian cancer Diseases 0.000 claims description 6
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
• 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 6
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
• 208000029742 colonic neoplasm Diseases 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
• 201000001441 melanoma Diseases 0.000 claims description 6
• 201000002528 pancreatic cancer Diseases 0.000 claims description 6
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
• 230000000087 stabilizing effect Effects 0.000 claims description 6
• 208000008732 thymoma Diseases 0.000 claims description 6
• 206010005003 Bladder cancer Diseases 0.000 claims description 5
• 206010006187 Breast cancer Diseases 0.000 claims description 5
• 208000026310 Breast neoplasm Diseases 0.000 claims description 5
• 235000010469 Glycine max Nutrition 0.000 claims description 5
• 208000034578 Multiple myelomas Diseases 0.000 claims description 5
• 206010029260 Neuroblastoma Diseases 0.000 claims description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
• 208000032839 leukemia Diseases 0.000 claims description 5
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
• 244000068988 Glycine max Species 0.000 claims description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
• 210000005056 cell body Anatomy 0.000 claims description 4
• 201000010881 cervical cancer Diseases 0.000 claims description 4
• 239000012141 concentrate Substances 0.000 claims description 4
• 201000010536 head and neck cancer Diseases 0.000 claims description 4
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
• 201000005202 lung cancer Diseases 0.000 claims description 4
• 208000020816 lung neoplasm Diseases 0.000 claims description 4
• 206010051747 multiple endocrine neoplasia Diseases 0.000 claims description 4
• 208000030507 AIDS Diseases 0.000 claims description 3
• 206010003571 Astrocytoma Diseases 0.000 claims description 3
• 206010004593 Bile duct cancer Diseases 0.000 claims description 3
• 208000019838 Blood disease Diseases 0.000 claims description 3
• 206010005949 Bone cancer Diseases 0.000 claims description 3
• 208000018084 Bone neoplasm Diseases 0.000 claims description 3
• 208000005243 Chondrosarcoma Diseases 0.000 claims description 3
• 201000009047 Chordoma Diseases 0.000 claims description 3
• 206010014967 Ependymoma Diseases 0.000 claims description 3
• 208000008961 Fibrous Dysplasia of Bone Diseases 0.000 claims description 3
• 206010053717 Fibrous histiocytoma Diseases 0.000 claims description 3
• 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
• 208000032612 Glial tumor Diseases 0.000 claims description 3
• 206010018338 Glioma Diseases 0.000 claims description 3
• 208000009164 Islet Cell Adenoma Diseases 0.000 claims description 3
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
• 206010024612 Lipoma Diseases 0.000 claims description 3
• 206010025323 Lymphomas Diseases 0.000 claims description 3
• 201000001853 McCune-Albright syndrome Diseases 0.000 claims description 3
• 208000000172 Medulloblastoma Diseases 0.000 claims description 3
• 241000699670 Mus sp. Species 0.000 claims description 3
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
• 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
• 206010060862 Prostate cancer Diseases 0.000 claims description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
• 208000008938 Rhabdoid tumor Diseases 0.000 claims description 3
• 206010073334 Rhabdoid tumour Diseases 0.000 claims description 3
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
• 206010057644 Testis cancer Diseases 0.000 claims description 3
• 201000009365 Thymic carcinoma Diseases 0.000 claims description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
• 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
• 208000001119 benign fibrous histiocytoma Diseases 0.000 claims description 3
• 208000012080 benign lipomatous neoplasm Diseases 0.000 claims description 3
• 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
• 210000000988 bone and bone Anatomy 0.000 claims description 3
• 210000004556 brain Anatomy 0.000 claims description 3
• 210000001715 carotid artery Anatomy 0.000 claims description 3
• 208000011654 childhood malignant neoplasm Diseases 0.000 claims description 3
• 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
• 201000010103 fibrous dysplasia Diseases 0.000 claims description 3
• 210000000232 gallbladder Anatomy 0.000 claims description 3
• 201000010175 gallbladder cancer Diseases 0.000 claims description 3
• 208000014951 hematologic disease Diseases 0.000 claims description 3
• 201000002529 islet cell tumor Diseases 0.000 claims description 3
• 201000005252 lipomatous cancer Diseases 0.000 claims description 3
• 206010024627 liposarcoma Diseases 0.000 claims description 3
• 201000007270 liver cancer Diseases 0.000 claims description 3
• 208000014018 liver neoplasm Diseases 0.000 claims description 3
• 208000030883 malignant astrocytoma Diseases 0.000 claims description 3
• 206010027191 meningioma Diseases 0.000 claims description 3
• 201000009500 myxoid chondrosarcoma Diseases 0.000 claims description 3
• 208000023833 nerve sheath neoplasm Diseases 0.000 claims description 3
• 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims description 3
• 208000028591 pheochromocytoma Diseases 0.000 claims description 3
• 208000010916 pituitary tumor Diseases 0.000 claims description 3
• 201000002267 posterior uveal melanoma Diseases 0.000 claims description 3
• 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
• 201000000849 skin cancer Diseases 0.000 claims description 3
• 201000011096 spinal cancer Diseases 0.000 claims description 3
• 208000014618 spinal cord cancer Diseases 0.000 claims description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
• 206010042863 synovial sarcoma Diseases 0.000 claims description 3
• 201000003120 testicular cancer Diseases 0.000 claims description 3
• 201000002510 thyroid cancer Diseases 0.000 claims description 3
• 208000025443 tumor of adipose tissue Diseases 0.000 claims description 3
• 208000017997 tumor of parathyroid gland Diseases 0.000 claims description 3
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
• 208000002193 Pain Diseases 0.000 claims description 2
• 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
• 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 2
• 238000010790 dilution Methods 0.000 claims description 2
• 239000012895 dilution Substances 0.000 claims description 2
• 239000013604 expression vector Substances 0.000 claims description 2
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
• 206010046766 uterine cancer Diseases 0.000 claims description 2
• 210000004291 uterus Anatomy 0.000 claims description 2
• 241000514450 Podocarpus latifolius Species 0.000 claims 2
• 241000159610 Roya <green alga> Species 0.000 claims 2
• 210000002445 nipple Anatomy 0.000 claims 2
• IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 claims 1
• 244000005894 Albizia lebbeck Species 0.000 claims 1
• 241000282421 Canidae Species 0.000 claims 1
• 206010010071 Coma Diseases 0.000 claims 1
• 235000008247 Echinochloa frumentacea Nutrition 0.000 claims 1
• 244000089409 Erythrina poeppigiana Species 0.000 claims 1
• 101000636705 Homo sapiens NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial Proteins 0.000 claims 1
• 241000087799 Koma Species 0.000 claims 1
• 101000831624 Locusta migratoria Locustatachykinin-1 Proteins 0.000 claims 1
• 102100031919 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial Human genes 0.000 claims 1
• 240000004072 Panicum sumatrense Species 0.000 claims 1
• CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical compound ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 claims 1
• 241001377010 Pila Species 0.000 claims 1
• 235000009776 Rathbunia alamosensis Nutrition 0.000 claims 1
• 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
• GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
• 238000009395 breeding Methods 0.000 claims 1
• 230000001488 breeding effect Effects 0.000 claims 1
• 244000240602 cacao Species 0.000 claims 1
• 241001233037 catfish Species 0.000 claims 1
• 201000010240 chromophobe renal cell carcinoma Diseases 0.000 claims 1
• 235000013305 food Nutrition 0.000 claims 1
• 208000003884 gestational trophoblastic disease Diseases 0.000 claims 1
• 235000021374 legumes Nutrition 0.000 claims 1
• 229910052754 neon Inorganic materials 0.000 claims 1
• GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 claims 1
• DDDQVDIPBFGVIG-UHFFFAOYSA-N plafibride Chemical compound C1COCCN1CNC(=O)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 DDDQVDIPBFGVIG-UHFFFAOYSA-N 0.000 claims 1
• 229950010439 plafibride Drugs 0.000 claims 1
• 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
• 230000002889 sympathetic effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 62
• 239000012634 fragment Substances 0.000 abstract description 44
• 230000028993 immune response Effects 0.000 abstract description 27
• 210000002865 immune cell Anatomy 0.000 abstract description 8
• 241000282567 Macaca fascicularis Species 0.000 abstract description 4
• 230000004936 stimulating effect Effects 0.000 abstract description 4
• 230000001105 regulatory effect Effects 0.000 abstract description 3
• 102000037982 Immune checkpoint proteins Human genes 0.000 abstract description 2
• 108091008036 Immune checkpoint proteins Proteins 0.000 abstract description 2
• 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 21
• 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 21
• 101100022187 Caenorhabditis elegans mab-10 gene Proteins 0.000 abstract 1
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 1
• 102000048362 human PDCD1 Human genes 0.000 abstract 1
• 102100026115 S-adenosylmethionine synthase isoform type-1 Human genes 0.000 description 953
• 108090000765 processed proteins & peptides Proteins 0.000 description 376
• 102000004196 processed proteins & peptides Human genes 0.000 description 318
• 229920001184 polypeptide Polymers 0.000 description 312
• 125000005647 linker group Chemical group 0.000 description 130
• 239000000427 antigen Substances 0.000 description 96
• 108091007433 antigens Proteins 0.000 description 95
• 102000036639 antigens Human genes 0.000 description 95
• 230000015572 biosynthetic process Effects 0.000 description 78
• 108091033319 polynucleotide Proteins 0.000 description 60
• 102000040430 polynucleotide Human genes 0.000 description 60
• 239000002157 polynucleotide Substances 0.000 description 60
• 235000001014 amino acid Nutrition 0.000 description 59
• 101710186153 S-adenosylmethionine synthase 2 Proteins 0.000 description 53
• 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 description 53
• 101710167557 S-adenosylmethionine synthase isoform type-2 Proteins 0.000 description 53
• 239000000833 heterodimer Substances 0.000 description 52
• 229940024606 amino acid Drugs 0.000 description 51
• 101710199257 Peripheral myelin protein 22 Proteins 0.000 description 50
• 102100035917 Peripheral myelin protein 22 Human genes 0.000 description 50
• 108090000623 proteins and genes Proteins 0.000 description 50
• 239000002773 nucleotide Substances 0.000 description 46
• 125000003729 nucleotide group Chemical group 0.000 description 46
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 44
• 101710186159 S-adenosylmethionine synthase 4 Proteins 0.000 description 43
• 101710186156 S-adenosylmethionine synthase 5 Proteins 0.000 description 43
• 102000004169 proteins and genes Human genes 0.000 description 43
• 235000018102 proteins Nutrition 0.000 description 42
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 40
• 230000006870 function Effects 0.000 description 37
• 102000005962 receptors Human genes 0.000 description 37
• 108020003175 receptors Proteins 0.000 description 37
• 230000001965 increasing effect Effects 0.000 description 36
• 108060003951 Immunoglobulin Proteins 0.000 description 34
• 125000000539 amino acid group Chemical group 0.000 description 34
• 102000018358 immunoglobulin Human genes 0.000 description 34
• 239000012636 effector Substances 0.000 description 33
• 239000000203 mixture Substances 0.000 description 32
• 235000018417 cysteine Nutrition 0.000 description 31
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 31
• 210000001744 T-lymphocyte Anatomy 0.000 description 30
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 24
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
• 230000000694 effects Effects 0.000 description 20
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 20
• 210000004899 c-terminal region Anatomy 0.000 description 19
• 201000010099 disease Diseases 0.000 description 19
• 239000003814 drug Substances 0.000 description 19
• 230000002401 inhibitory effect Effects 0.000 description 19
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 18
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 18
• 210000000987 immune system Anatomy 0.000 description 16
• 241000282553 Macaca Species 0.000 description 15
• 101150036800 SOV gene Proteins 0.000 description 15
• 230000003993 interaction Effects 0.000 description 15
• 238000004519 manufacturing process Methods 0.000 description 15
• 230000001404 mediated effect Effects 0.000 description 15
• 210000001519 tissue Anatomy 0.000 description 15
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 14
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 14
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 14
• 239000004472 Lysine Substances 0.000 description 14
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 14
• 241001465754 Metazoa Species 0.000 description 13
• 230000013595 glycosylation Effects 0.000 description 13
• 238000006206 glycosylation reaction Methods 0.000 description 13
• 208000015181 infectious disease Diseases 0.000 description 13
• 230000001225 therapeutic effect Effects 0.000 description 13
• 239000003446 ligand Substances 0.000 description 12
• 230000035755 proliferation Effects 0.000 description 12
• 102000004127 Cytokines Human genes 0.000 description 11
• 108090000695 Cytokines Proteins 0.000 description 11
• 238000011955 best available control technology Methods 0.000 description 11
• 229940079593 drug Drugs 0.000 description 11
• 238000005516 engineering process Methods 0.000 description 11
• 230000005764 inhibitory process Effects 0.000 description 11
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 10
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 10
• 150000001720 carbohydrates Chemical class 0.000 description 10
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
• 241000282412 Homo Species 0.000 description 9
• 101001000631 Homo sapiens Peripheral myelin protein 22 Proteins 0.000 description 9
• 101100491259 Oryza sativa subsp. japonica AP2-2 gene Proteins 0.000 description 9
• 230000003213 activating effect Effects 0.000 description 9
• 210000003719 b-lymphocyte Anatomy 0.000 description 9
• 230000028327 secretion Effects 0.000 description 9
• 239000013598 vector Substances 0.000 description 9
• 108010088751 Albumins Proteins 0.000 description 8
• 102000009027 Albumins Human genes 0.000 description 8
• 241001529936 Murinae Species 0.000 description 8
• 101001041541 Romalea microptera RO-1 Proteins 0.000 description 8
• 230000005867 T cell response Effects 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 230000000875 corresponding effect Effects 0.000 description 8
• 230000007423 decrease Effects 0.000 description 8
• 238000010188 recombinant method Methods 0.000 description 8
• 230000009870 specific binding Effects 0.000 description 8
• 230000003612 virological effect Effects 0.000 description 8
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
• 241000283984 Rodentia Species 0.000 description 7
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
• 101800001707 Spacer peptide Proteins 0.000 description 7
• 230000004913 activation Effects 0.000 description 7
• 239000005557 antagonist Substances 0.000 description 7
• 230000000890 antigenic effect Effects 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 230000000295 complement effect Effects 0.000 description 7
• 238000013270 controlled release Methods 0.000 description 7
• 230000002163 immunogen Effects 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 239000000523 sample Substances 0.000 description 7
• 229940124597 therapeutic agent Drugs 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• 241000282465 Canis Species 0.000 description 6
• 101000840540 Homo sapiens Iduronate 2-sulfatase Proteins 0.000 description 6
• 241000699666 Mus <mouse, genus> Species 0.000 description 6
• 239000008186 active pharmaceutical agent Substances 0.000 description 6
• 230000033228 biological regulation Effects 0.000 description 6
• 235000014633 carbohydrates Nutrition 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 230000003834 intracellular effect Effects 0.000 description 6
• 230000026731 phosphorylation Effects 0.000 description 6
• 238000006366 phosphorylation reaction Methods 0.000 description 6
• KNVAYBMMCPLDOZ-UHFFFAOYSA-N propan-2-yl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OC(C)C KNVAYBMMCPLDOZ-UHFFFAOYSA-N 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• 239000004475 Arginine Substances 0.000 description 5
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
• 241000206761 Bacillariophyta Species 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 239000004471 Glycine Substances 0.000 description 5
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
• 101100298048 Mus musculus Pmp22 gene Proteins 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 230000006044 T cell activation Effects 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 210000000612 antigen-presenting cell Anatomy 0.000 description 5
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
• 235000009582 asparagine Nutrition 0.000 description 5
• 229960001230 asparagine Drugs 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 238000010276 construction Methods 0.000 description 5
• 230000016396 cytokine production Effects 0.000 description 5
• 238000013461 design Methods 0.000 description 5
• 238000011049 filling Methods 0.000 description 5
• 229940072221 immunoglobulins Drugs 0.000 description 5
• 239000007943 implant Substances 0.000 description 5
• 238000001802 infusion Methods 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 238000013268 sustained release Methods 0.000 description 5
• 239000012730 sustained-release form Substances 0.000 description 5
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
• 241000196324 Embryophyta Species 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 102100031351 Galectin-9 Human genes 0.000 description 4
• 101710121810 Galectin-9 Proteins 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
• 241000288906 Primates Species 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 150000001875 compounds Chemical class 0.000 description 4
• 230000000139 costimulatory effect Effects 0.000 description 4
• 238000004132 cross linking Methods 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 210000004443 dendritic cell Anatomy 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000006471 dimerization reaction Methods 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 150000002270 gangliosides Chemical class 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 210000004072 lung Anatomy 0.000 description 4
• 210000000822 natural killer cell Anatomy 0.000 description 4
• 150000002482 oligosaccharides Chemical class 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 238000013207 serial dilution Methods 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 238000010189 synthetic method Methods 0.000 description 4
• FHDAHQFLZOYWQM-QDYAWOJKSA-N (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2S)-1-imidazol-1-ylpropan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol Chemical compound C[C@H](Cn1ccnc1)[C@H]2CC[C@H]3\C(=C\C=C4C[C@@H](O)C(=C)[C@H](O)C4)\CCC[C@]23C FHDAHQFLZOYWQM-QDYAWOJKSA-N 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 208000011691 Burkitt lymphomas Diseases 0.000 description 3
• 108010075254 C-Peptide Proteins 0.000 description 3
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• 101800000194 Growth hormone-binding protein Proteins 0.000 description 3
• 102400001066 Growth hormone-binding protein Human genes 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 230000004989 O-glycosylation Effects 0.000 description 3
• 206010057249 Phagocytosis Diseases 0.000 description 3
• 101710186160 S-adenosylmethionine synthase 3 Proteins 0.000 description 3
• 101100451406 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HPM1 gene Proteins 0.000 description 3
• 108091008874 T cell receptors Proteins 0.000 description 3
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
• 239000003708 ampul Substances 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 230000008030 elimination Effects 0.000 description 3
• 238000003379 elimination reaction Methods 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 230000005714 functional activity Effects 0.000 description 3
• 235000013922 glutamic acid Nutrition 0.000 description 3
• 239000004220 glutamic acid Substances 0.000 description 3
• 210000004408 hybridoma Anatomy 0.000 description 3
• 229940127121 immunoconjugate Drugs 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 238000005304 joining Methods 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 239000008176 lyophilized powder Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 3
• 239000011859 microparticle Substances 0.000 description 3
• 238000004091 panning Methods 0.000 description 3
• 230000001717 pathogenic effect Effects 0.000 description 3
• 229960002621 pembrolizumab Drugs 0.000 description 3
• 230000008782 phagocytosis Effects 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 150000003839 salts Chemical group 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 230000008054 signal transmission Effects 0.000 description 3
• 230000008093 supporting effect Effects 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 210000002993 trophoblast Anatomy 0.000 description 3
• 210000004881 tumor cell Anatomy 0.000 description 3
• 229960005486 vaccine Drugs 0.000 description 3
• 230000003313 weakening effect Effects 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 230000003844 B-cell-activation Effects 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 101100340271 Caenorhabditis elegans ida-1 gene Proteins 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 2
• 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 208000006168 Ewing Sarcoma Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 241000711549 Hepacivirus C Species 0.000 description 2
• 241000709721 Hepatovirus A Species 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 2
• 108091006905 Human Serum Albumin Proteins 0.000 description 2
• 102000008100 Human Serum Albumin Human genes 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 101150079855 MAK5 gene Proteins 0.000 description 2
• 102100038560 Maleylacetoacetate isomerase Human genes 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 102000007298 Mucin-1 Human genes 0.000 description 2
• 108010008707 Mucin-1 Proteins 0.000 description 2
• 108010063954 Mucins Proteins 0.000 description 2
• 102000015728 Mucins Human genes 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 101800004937 Protein C Proteins 0.000 description 2
• 102000017975 Protein C Human genes 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 208000015634 Rectal Neoplasms Diseases 0.000 description 2
• XDXHAEQXIBQUEZ-UHFFFAOYSA-N Ropinirole hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 XDXHAEQXIBQUEZ-UHFFFAOYSA-N 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 101800001700 Saposin-D Proteins 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• 241001415849 Strigiformes Species 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• -1 amino acid aspartate Chemical class 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 201000010897 colon adenocarcinoma Diseases 0.000 description 2
• 238000010668 complexation reaction Methods 0.000 description 2
• 238000012926 crystallographic analysis Methods 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 238000010353 genetic engineering Methods 0.000 description 2
• 102000054766 genetic haplotypes Human genes 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 201000009277 hairy cell leukemia Diseases 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 239000000710 homodimer Substances 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 230000003308 immunostimulating effect Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 230000004068 intracellular signaling Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 230000021633 leukocyte mediated immunity Effects 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 108010035293 maleylacetoacetate isomerase Proteins 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 210000003071 memory t lymphocyte Anatomy 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 229960003301 nivolumab Drugs 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 230000001590 oxidative effect Effects 0.000 description 2
• 210000002741 palatine tonsil Anatomy 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 229920002704 polyhistidine Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 238000004393 prognosis Methods 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• 229960000856 protein c Drugs 0.000 description 2
• 238000001742 protein purification Methods 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 206010038038 rectal cancer Diseases 0.000 description 2
• 201000001275 rectum cancer Diseases 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 238000009097 single-agent therapy Methods 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 125000006850 spacer group Chemical group 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 238000012916 structural analysis Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
• PFFIDZXUXFLSSR-UHFFFAOYSA-N 1-methyl-N-[2-(4-methylpentan-2-yl)-3-thienyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound S1C=CC(NC(=O)C=2C(=NN(C)C=2)C(F)(F)F)=C1C(C)CC(C)C PFFIDZXUXFLSSR-UHFFFAOYSA-N 0.000 description 1
• HHOJVZAEHZGDRB-UHFFFAOYSA-N 2-(4,6-diamino-1,3,5-triazin-2-yl)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC1=NC(N)=NC(N)=N1 HHOJVZAEHZGDRB-UHFFFAOYSA-N 0.000 description 1
• MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
• 101001015038 Albizia kalkora Kunitz-type trypsin inhibitor alpha chain Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 241001465677 Ancylostomatoidea Species 0.000 description 1
• 101100049050 Arabidopsis thaliana PVA41 gene Proteins 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 241001073224 Baeopogon indicator Species 0.000 description 1
• 108060000903 Beta-catenin Proteins 0.000 description 1
• 102000015735 Beta-catenin Human genes 0.000 description 1
• 241000283725 Bos Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101710117545 C protein Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102100032616 Caspase-2 Human genes 0.000 description 1
• 241000499489 Castor canadensis Species 0.000 description 1
• 241000242722 Cestoda Species 0.000 description 1
• 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 241001327708 Coriaria sarmentosa Species 0.000 description 1
• 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 1
• 206010012186 Delayed delivery Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 101710204425 Enterotoxin type B Proteins 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 208000014770 Foot disease Diseases 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 244000194101 Ginkgo biloba Species 0.000 description 1
• 235000008100 Ginkgo biloba Nutrition 0.000 description 1
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000867612 Homo sapiens Caspase-2 Proteins 0.000 description 1
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
• 101000802660 Homo sapiens Histo-blood group ABO system transferase Proteins 0.000 description 1
• 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
• 101000668140 Homo sapiens RNA-binding protein 8A Proteins 0.000 description 1
• 101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 description 1
• 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
• GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010058683 Immobilized Proteins Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000005712 Keratin-8 Human genes 0.000 description 1
• 108010070511 Keratin-8 Proteins 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 101150104182 MOB2 gene Proteins 0.000 description 1
• 101000845005 Macrovipera lebetina Disintegrin lebein-2-alpha Proteins 0.000 description 1
• 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
• 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
• 102000003735 Mesothelin Human genes 0.000 description 1
• 108090000015 Mesothelin Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 101710116852 Molybdenum cofactor sulfurase 1 Proteins 0.000 description 1
• 101100286255 Mus musculus Id2 gene Proteins 0.000 description 1
• 101100456571 Mus musculus Med12 gene Proteins 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
• 102000004140 Oncostatin M Human genes 0.000 description 1
• 108090000630 Oncostatin M Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 206010033963 Parathyroid tumour Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 244000046052 Phaseolus vulgaris Species 0.000 description 1
• 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 241000364051 Pima Species 0.000 description 1
• 241000242594 Platyhelminthes Species 0.000 description 1
• 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 241000394658 Prymnesium kappa Species 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 102100039691 RNA-binding protein 8A Human genes 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 241000022563 Rema Species 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 241000606651 Rickettsiales Species 0.000 description 1
• 101150081243 STA1 gene Proteins 0.000 description 1
• 241000124033 Salix Species 0.000 description 1
• 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
• 240000005499 Sasa Species 0.000 description 1
• 241001289920 Sassia Species 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 241001575049 Sonia Species 0.000 description 1
• 241000408490 Sovia Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 201000008736 Systemic mastocytosis Diseases 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 102000007238 Transferrin Receptors Human genes 0.000 description 1
• 108010033576 Transferrin Receptors Proteins 0.000 description 1
• 241000869417 Trematodes Species 0.000 description 1
• 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
• 102100033579 Trophoblast glycoprotein Human genes 0.000 description 1
• 101710190034 Trophoblast glycoprotein Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
• CCAZWUJBLXKBAY-ULZPOIKGSA-N Tutin Chemical compound C([C@]12[C@@H]3O[C@@H]3[C@@]3(O)[C@H]4C(=O)O[C@@H]([C@H]([C@]32C)O)[C@H]4C(=C)C)O1 CCAZWUJBLXKBAY-ULZPOIKGSA-N 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 241000711975 Vesicular stomatitis virus Species 0.000 description 1
• 102100026497 Zinc finger protein 654 Human genes 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 210000005006 adaptive immune system Anatomy 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 150000001483 arginine derivatives Chemical class 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 150000001508 asparagines Chemical class 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 230000009460 calcium influx Effects 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 229940022399 cancer vaccine Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 230000010001 cellular homeostasis Effects 0.000 description 1
• 230000009920 chelation Effects 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 238000009104 chemotherapy regimen Methods 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 201000000292 clear cell sarcoma Diseases 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 210000004953 colonic tissue Anatomy 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 1
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000008260 defense mechanism Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 230000005292 diamagnetic effect Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 125000002228 disulfide group Chemical group 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 210000001163 endosome Anatomy 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 231100000655 enterotoxin Toxicity 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 108060002566 ephrin Proteins 0.000 description 1
• 102000012803 ephrin Human genes 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 210000004709 eyebrow Anatomy 0.000 description 1
• 210000004700 fetal blood Anatomy 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 150000002333 glycines Chemical class 0.000 description 1
• 201000003872 goiter Diseases 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 102000057422 human IDS Human genes 0.000 description 1
• 102000012427 human indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
• 235000020256 human milk Nutrition 0.000 description 1
• 210000004251 human milk Anatomy 0.000 description 1
• 238000011577 humanized mouse model Methods 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 230000008348 humoral response Effects 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
• GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
• 229940097277 hygromycin b Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000005934 immune activation Effects 0.000 description 1
• 229940049705 immune stimulating antibody conjugate Drugs 0.000 description 1
• 230000008629 immune suppression Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 108091008042 inhibitory receptors Proteins 0.000 description 1
• 229960000367 inositol Drugs 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 235000014413 iron hydroxide Nutrition 0.000 description 1
• NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical class [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 230000029226 lipidation Effects 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 238000001693 membrane extraction with a sorbent interface Methods 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 108010071421 milk fat globule Proteins 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 230000009149 molecular binding Effects 0.000 description 1
• 238000003032 molecular docking Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 210000002200 mouth mucosa Anatomy 0.000 description 1
• 229940051875 mucins Drugs 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 230000037311 normal skin Effects 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 230000014207 opsonization Effects 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 229940127084 other anti-cancer agent Drugs 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 210000004923 pancreatic tissue Anatomy 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000008238 pharmaceutical water Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 150000003906 phosphoinositides Chemical class 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
• 231100000614 poison Toxicity 0.000 description 1
• 239000002574 poison Substances 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 239000004584 polyacrylic acid Substances 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 230000027317 positive regulation of immune response Effects 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 238000012207 quantitative assay Methods 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000012121 regulation of immune response Effects 0.000 description 1
• 230000010425 regulation of immunoglobulin secretion Effects 0.000 description 1
• 230000006716 regulation of lymphocyte proliferation Effects 0.000 description 1
• 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
• 210000005084 renal tissue Anatomy 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 229940102127 rubidium chloride Drugs 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 229920000260 silastic Polymers 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 235000021309 simple sugar Nutrition 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 238000010532 solid phase synthesis reaction Methods 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 230000003335 steric effect Effects 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000006433 tumor necrosis factor production Effects 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 235000008979 vitamin B4 Nutrition 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1